GSK plc (GSK)

GSK plc receives EU approval for Exdensur in severe asthma and CRSwNP, and launches a significant buyback program. The stock price is near a 52-week high, with positive sentiment surrounding regulatory approvals.

About GSK plc

GSK plc is a multinational pharmaceutical and biotechnology company.
GSK plc uses the ticker $GSK for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

• GSK plc (GSK) Galaxy Score™ is up 142.86% from the previous month.
• GSK plc (GSK) sentiment is up 38.33% from the previous [--] months.
• GSK plc Price hit a 52-Week high of $61.70 for the hour
• GSK plc Price hit an all time of $61.70 for the hour

Price: $61.40

Price 24-Hour Time-Series Raw Data
The stock price is near a 52-week high, supported by positive news like the FDA approval of Blenrep and recent acquisitions, as well as EU approval for Exdensur and a buyback program. However, potential volatility exists due to Blenrep's label restrictions.

24-Hour: 0.87% 7-Day: 4.34% 30-Day: 28.79%

1-Year High: $61.60 on 2026-02-18
1-Year Low: $33.60 on 2025-04-10

AltRank: [-----]

AltRank 24-Hour Time-Series Raw Data
GSK plc (GSK) is currently AltRank #1,209 based on combined combined social and market metrics Daily Average: [---]
[--] Week: [-----] +439
[--] Month: [-----] +770
[--] Months: [-----] +138
[--] Year: [-----] +737
1-Year High: [-----] on 2026-01-31
1-Year Low: [--] on 2025-06-08

Galaxy Score: [-----]

Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +21
[--] Month: [--] +40
[--] Months: [--] +42
[--] Year: [--] +6
1-Year High: [--] on 2025-05-13
1-Year Low: [--] on 2025-07-03

Engagements: [-----] (24h)

Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [------] -59%
[--] Month: [-------] +218%
[--] Months: [---------] +1.40%
[--] Year: [---------] -1.60%
1-Year High: [-------] on 2025-07-30
1-Year Low: [---] on 2025-12-07

Engagements by network (24h): Reddit: [--] X: [-----] YouTube: [--]

Mentions: [---] (24h)

Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [---] -14%
[--] Month: [---] +65%
[--] Months: [-----] -28%
[--] Year: [-----] +55%
1-Year High: [---] on 2025-08-03
1-Year Low: [--] on 2025-12-07

Mentions by network (24h): Reddit: [--] X: [---] YouTube: [--]

Creators: [---] (24h)

Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning GSK plc (GSK) in the last [--] hours which is up 72% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [---] -8.80%
[--] Month: [---] +78%
[--] Months: [-----] -17%
[--] Year: [-----] +58%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-12-07

The most influential creators that mention GSK plc in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@Briefingcom	[--]	[------]	[--]	[-----]
@ValueSense_io	[--]	[------]	[--]	[-----]
@MarcJacksonLA	[--]	[-----]	[--]	[---]
@BioStocks	[--]	[-------]	[--]	[---]
@Tickeron	[--]	[------]	[--]	[--]
@doepke_michel	[--]	[-----]	[--]	[--]
@MiraNunes70748	[--]	[-------]	[--]	[--]
@ChartMill	[--]	[------]	[--]	[--]
@insiderscreener	[--]	[-----]	[--]	[--]

View More

Sentiment: 71%

Sentiment 24-Hour Time-Series Raw Data
Current Value: 71%
Daily Average: 73%
[--] Week: 100% +14%
[--] Month: 83% +9%
[--] Months: 83% +23%
[--] Year: 83% +12%
1-Year High: 100% on 2025-03-21
1-Year Low: 37% on 2025-12-02

Most Supportive Themes:

• FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone.
• Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach.

Most Critical Themes:

• Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration.
• Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials.

Social Dominance: 0.011%

Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.011%
Daily Average: 0.02%
[--] Week: 0.029% -0.0014%
[--] Month: 0.016% +0.0047%
[--] Months: 0.016% -0.0037%
[--] Year: 0.016% -0.0094%
1-Year High: 0.067% on 2025-08-03
1-Year Low: 0.0024% on 2025-12-07

Market Dominance: 0.139%

Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.139%
Daily Average: 3%
1-Year High: 5.60% on 2026-02-06
1-Year Low: 0.119% on 2025-03-19

Market Cap: $123,147,629,236

Market Cap 24-Hour Time-Series Raw Data
Current Value: $123,147,629,236
Daily Average: $85,981,059,845
[--] Week: $123,548,957,668 +4.40%
[--] Month: $123,548,957,668 +27%
[--] Months: $123,548,957,668 +53%
[--] Year: $123,548,957,668 +65%
1-Year High: $123,528,891,246 on 2026-02-18
1-Year Low: $68,072,746,997 on 2025-04-10

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing